Jefferies Financial Group Reiterates “Buy” Rating for LifeStance Health Group (NASDAQ:LFST)

LifeStance Health Group (NASDAQ:LFSTGet Rating)‘s stock had its “buy” rating reiterated by investment analysts at Jefferies Financial Group in a research report issued on Monday, Benzinga reports.

Other research analysts also recently issued research reports about the stock. Cowen dropped their price objective on shares of LifeStance Health Group from $11.00 to $10.00 in a report on Monday, August 22nd. Cowen lowered their target price on shares of LifeStance Health Group from $11.00 to $10.00 and set an “outperform” rating on the stock in a research note on Monday, August 22nd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $10.33.

LifeStance Health Group Trading Down 2.1 %

Shares of NASDAQ:LFST opened at $7.16 on Monday. The firm has a fifty day moving average of $7.64 and a two-hundred day moving average of $7.03. The firm has a market capitalization of $2.69 billion, a P/E ratio of -6.88 and a beta of 0.89. LifeStance Health Group has a 12-month low of $4.77 and a 12-month high of $11.30. The company has a quick ratio of 2.19, a current ratio of 2.19 and a debt-to-equity ratio of 0.13.

LifeStance Health Group (NASDAQ:LFSTGet Rating) last issued its earnings results on Tuesday, August 9th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). The company had revenue of $209.53 million for the quarter, compared to analyst estimates of $212.47 million. LifeStance Health Group had a negative net margin of 46.31% and a negative return on equity of 23.33%. The company’s quarterly revenue was up 30.5% on a year-over-year basis. During the same period last year, the business earned ($0.17) EPS. On average, equities analysts expect that LifeStance Health Group will post -0.66 EPS for the current fiscal year.

Insider Transactions at LifeStance Health Group

In related news, insider Warren Gouk sold 34,449 shares of the stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $7.00, for a total value of $241,143.00. Following the transaction, the insider now directly owns 6,110,299 shares in the company, valued at $42,772,093. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, insider Warren Gouk sold 34,449 shares of the stock in a transaction on Tuesday, September 6th. The shares were sold at an average price of $7.00, for a total transaction of $241,143.00. Following the completion of the sale, the insider now owns 6,110,299 shares of the company’s stock, valued at $42,772,093. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kevin Michael Mullins sold 82,520 shares of the stock in a transaction on Friday, September 30th. The stock was sold at an average price of $7.03, for a total transaction of $580,115.60. Following the sale, the insider now directly owns 5,584,540 shares of the company’s stock, valued at approximately $39,259,316.20. The disclosure for this sale can be found here. Over the last three months, insiders have sold 261,397 shares of company stock worth $1,967,125. Corporate insiders own 16.59% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. increased its position in shares of LifeStance Health Group by 56.6% during the first quarter. Ameritas Investment Partners Inc. now owns 5,575 shares of the company’s stock worth $56,000 after acquiring an additional 2,016 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in LifeStance Health Group in the second quarter valued at $37,000. Amalgamated Bank bought a new position in LifeStance Health Group in the first quarter valued at $84,000. Point72 Hong Kong Ltd bought a new position in LifeStance Health Group in the second quarter valued at $63,000. Finally, Dimensional Fund Advisors LP bought a new position in LifeStance Health Group in the first quarter valued at $130,000. Institutional investors own 78.05% of the company’s stock.

About LifeStance Health Group

(Get Rating)

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

Featured Articles

Analyst Recommendations for LifeStance Health Group (NASDAQ:LFST)

Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.